SAN FRANCISCO - Hims & Hers Health, Inc. (NYSE: HIMS), a prominent health and wellness platform, today announced the addition of Anja Manuel to its Board of Directors. Ms. Manuel, co-founder and principal at Rice, Hadley, Gates & Manuel LLC, brings a wealth of experience in government relations, foreign policy, technology policy, international markets, and governance to the board.
Anja Manuel's background includes roles as a U.S. government official and a strategic consultant for U.S. companies dealing with international markets and regulatory issues. Her expertise is expected to be a significant asset to Hims & Hers as they seek to expand their personalized healthcare services both domestically and internationally.
Andrew Dudum, CEO and co-founder of Hims & Hers, expressed confidence that Manuel's knowledge will complement the existing board and accelerate the company's mission to improve health outcomes. Manuel also shared her enthusiasm for joining the company, emphasizing her commitment to guiding its international growth.
Manuel's extensive board experience includes her current position at Ripple Labs, Inc., and past service on the board of Overseas Shipping Group, Inc. She is also the Executive Director of the Aspen Strategy Group and Aspen Security Forum, has served as a diplomat, attorney, and investment banker, and is an accomplished author and academic.
Hims & Hers has been recognized for its innovative approach to personalized healthcare, addressing conditions that affect millions of Americans. The company emphasizes the importance of individualized care, aiming to make a positive impact on how people feel in their bodies and minds.
This announcement is based on a press release statement from Hims & Hers Health, Inc.
InvestingPro Insights
In light of Hims & Hers Health, Inc.'s strategic move to enhance its board with Anja Manuel's expertise, investors may take an interest in the company's recent financial performance and market position. According to InvestingPro data, Hims & Hers has a market capitalization of $2.97 billion, reflecting its significant presence in the health and wellness sector. Moreover, the company has demonstrated robust revenue growth, with a 55.65% increase over the last twelve months as of Q1 2024, and a quarterly revenue growth of 45.81% in Q1 2024.
From the perspective of profitability and valuation, Hims & Hers is currently trading at a high Price / Book multiple of 8.61, which may suggest a premium valuation by the market. This is further supported by a striking 79.51% price total return over the last six months, alongside a substantial three-month price total return of 37.99%. These figures underscore the positive investor sentiment and the company's growth trajectory.
InvestingPro Tips highlight several key factors that are pivotal to the company's outlook. Management's proactive approach to share buybacks indicates a strong belief in the company's value proposition. Additionally, analysts have revised their earnings upwards for the upcoming period, and there is a consensus that Hims & Hers will become profitable this year. With liquid assets surpassing short-term obligations, the company appears to be in a healthy financial position to pursue its expansion goals.
For those interested in a deeper analysis, InvestingPro offers more tips on Hims & Hers, including insights into its debt levels, profitability, and valuation multiples. Subscribers can access these insights to make more informed investment decisions. To get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24. There are 11 additional InvestingPro Tips available for Hims & Hers at https://www.investing.com/pro/HIMS.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.